ANALYSIS OF ADVANTAGES AND DISADVANTAGES OF MODERN HYPOGLYCEMIC DRUGS
Abstract
More alternatives for treating type 2 diabetes (T2DM) are provided by new hypoglycemic medications, such as sodium-glucose cotransporter 2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucagon-like peptide 1 receptor agonists (GLP-1RA). They are usually well tolerated, though occasionally care must be used. In prediabetes and type 2 diabetes, combination therapy with novel hypoglycemic medications has demonstrated satisfactory glucose control in clinical studies (mainly traditional stepwise therapy); however, early combination therapy seems to offer faster, greater, and longer-lasting advantages. Now that oral semaglutide is widely used in clinical settings, it's time to create combination medications that include novel hypoglycemic medications, particularly SGLT-2i and/or GLP-1RA, to reduce the risk of prediabetes, newly diagnosed type 2 diabetes, and its cardiovascular complications while increasing patient compliance. SGLT-2i protects against heart failure through both direct and indirect effects, according to preclinical and clinical research. More research is required to determine how this all-encompassing protective effect controls the dynamic alterations of cardiac genes. From the standpoint of "clinical drug-mechanism-intensive disease treatment," we offer suggestions for the creation of medications for heart failure. This will expedite the creation of medications for heart failure and, to some extent, direct their usage. Patients with type 2 diabetes who fast during Ramadan benefit clinically from the newer glucose-lowering drugs, according to this systematic review and meta-analysis.
Keywords
GLP-1RA, SGLT-2i, DPP-4i, type 2 diabetes, combination medicine, hypoglycemic medications, thiazolidinediones, sulfonylureas, incretin mimetic medications.How to Cite
References
Ni X, Zhang L, Feng X, Tang L. New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. Front Pharmacol. 2022 Jun 8;13:877797. doi: 10.3389/fphar.2022.877797.
Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G. Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. Pharmaceuticals. 2010; 3(9):3005-3020. https://doi.org/10.3390/ph3093005
Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol (2016) 12(10):616–22. doi: 10.1038/nrendo.2016.105
Hu FB, Satija A, Manson JE. Curbing the diabetes pandemic: the need for global policy solutions. Jama (2015) 313(23):2319–20. doi: 10.1001/jama.2015.5287
Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol (2020) 16(7):377–90. doi: 10.1038/s41581-020-0278-5
Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR, Walker J, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol (2019) 7(12):938–48. doi: 10.1016/S2213-8587(19)30081-6
van Raalte DH, Verchere CB. Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest? Diab Obes Metab (2017) 19(9):1205–13. doi: 10.1111/dom.12935
Prattichizzo F, Ceriello A. Is time ready for combination therapy at diagnosis of type 2 diabetes? Diabetes/metabolism Res Rev (2021) 37(5):e3460. doi: 10.1002/dmrr.3460
Bluestone JA, Buckner JH, Herold KC. Immunotherapy: Building a bridge to a cure for type 1 diabetes. Science (2021) 373(6554):510–6. doi: 10.1126/science.abh1654
Pugliese A. Autoreactive T cells in type 1 diabetes. J Clin Invest (2017) 127(8):2881–91. doi: 10.1172/JCI94549
Chu X, Janssen AWM, Koenen H, Chang L, He X, Joosten I, et al. A genome-wide functional genomics approach uncovers genetic determinants of immune phenotypes in type 1 diabetes. eLife (2022) 11:e73709. doi: 10.7554/eLife.73709.sa2
Wallet MA, Santostefano KE, Terada N, Brusko TM. Isogenic cellular systems model the impact of genetic risk variants in the pathogenesis of type 1 diabetes. Front Endocrinol (2017) 8:276. doi: 10.3389/fendo.2017.00276
Zhou H, Sun L, Zhang S, Zhao X, Gang X, Wang G. Evaluating the causal role of gut microbiota in type 1 diabetes and its possible pathogenic mechanisms. Front Endocrinol (2020) 11:125. doi: 10.3389/fendo.2020.00125
Alexanian M., Przytycki P. F., Micheletti R., Padmanabhan A., Ye L., Travers J. G., et al. (2021). A Transcriptional Switch Governs Fibroblast Activation in Heart Disease. Nature 595, 438–443. 10.1038/s41586-021-03674-1
American Diabetes Association Professional Practice C., Draznin B., Aroda V. R., Bakris G., Benson G., Brown F. M., et al. (2022). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care 45, S125–S143. 10.2337/dc22-S009
Anker S. D., Butler J., Filippatos G., Ferreira J. P., Bocchi E., Böhm M., et al. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med. 385, 1451–1461. 10.1056/NEJMoa2107038
Feng X., Chen W., Ni X., Little P. J., Xu S., Tang L., et al. (2021). Metformin, Macrophage Dysfunction and Atherosclerosis. Front. Immunol. 12, 682853. 10.3389/fimmu.2021.682853
Matthews D. R., Paldánius P. M., Proot P., Chiang Y., Stumvoll M., Del Prato S., et al. (2019). Glycaemic Durability of an Early Combination Therapy with Vildagliptin and Metformin versus Sequential Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes (VERIFY): a 5-year, Multicentre, Randomised, Double-Blind Trial. Lancet 394, 1519–1529. 10.1016/S0140-6736(19)32131-2
Neuen B. L., Young T., Heerspink H. J. L., Neal B., Perkovic V., Billot L., et al. (2019). SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with Type 2 Diabetes: a Systematic Review and Meta-Analysis. Lancet Diabetes Endocrinol. 7, 845–854. 10.1016/S2213-8587(19)30256-6
Packer M., Anker S. D., Butler J., Filippatos G., Pocock S. J., Carson P., et al. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N. Engl. J. Med. 383, 1413–1424. 10.1056/NEJMoa2022190
Schiattarella G. G., Bode D. (2021). Canagliflozin and Myocardial Oxidative Stress: SGLT1 Inhibition Takes Centre Stage. Eur. Heart J. 42, 4961–4963. 10.1093/eurheartj/ehab519
Wilding J. P. H., Batterham R. L., Calanna S., Davies M., Van Gaal L. F., Lingvay I., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N. Engl. J. Med. 384, 989. 10.1056/NEJMoa2032183
License
Copyright (c) 2025 Iroda Brodarovna Takhirova, Shakhlo Bakhtiyorovna Qakhkharova
This work is licensed under a Creative Commons Attribution 4.0 International License.
